ESR1 and neoplasm: Given the findings of a more aggressive tumor phenotype in TEXhi ER+ tumors, including decreased estrogen response–related gene expression, we hypothesized that survival characteristics may be different in premenopausal and postmenopausal patients with ER+ BC.